ArticleJournal of Cancer2019

Antitumor activity of histone deacetylase inhibitor chidamide alone or in combination with epidermal growth factor receptor tyrosine kinase inhibitor icotinib in NSCLC.

Ningning Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.